home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Host-To-Graft Disease Spread In Parkinson Disease?

 
  April, 17 2008 7:25
your information resource in human molecular genetics
 
     

Cell transplants have long been proposed as a possible therapy for Parkinson disease, but a series of reports in Nature Medicine suggest that the pathology may spread from the host to the transplants.

Parkinson disease results from the abnormal aggregation of a protein known as alpha-synuclein and the degeneration of the substantia nigra, a dopamine-releasing region of the midbrain. Therapies for the disease aiming at replacing the lost cells have given hope and, in the 1990s, clinical trials transplanting dopaminergic fetal brain tissue into the brains of patients with Parkinson took place.

Two independent groups led by Patrik Brundin and by Jeffrey Kordower report that the transplanted tissue in some subjects shows evidence of alpha-synuclein aggregates. This observation is striking because the grafts were too young to develop this on their own, and the fetal tissue had been placed into the striatum, a brain region that receives input from the substantia nigra but does not develop alpha-synuclein aggregates in Parkinson disease. So, in these subjects, the disease seems to have spread from the host to the graft.

But not all studies agree. A third study, led by Ole Isacson, failed to show Parkinson-like pathology in the transplants from a different set of similar subjects, finding instead a large proportion of serotonergic, and not only dopaminergic, neurons within the grafts.

As current efforts to develop cell-replacement therapies focus on the use of stem cells to generate substantia nigra-like dopaminergic neurons, the findings of these three groups on long-term transplant recipients add a level of complexity to the idea of curing Parkinson disease with grafted tissue.

Author contacts:

Patrik Brundin (Wallenberg Neuroscience Center, Lund, Sweden)
E-mail: patrik.brundin@med.lu.se

Jeffrey Kordower (Rush University Medical Center, Chicago, IL, USA)
E-mail: jkordowe@rush.edu

Ole Isacson (Harvard Medical School/McLean Hospital, Belmont, MA, USA)
E-mail: isacson@hms.harvard.edu

Abstracts available online:

Abstract of Paper 1.
Abstract of Paper 2.
Abstract of Paper 3.

(C) Nature Medicine press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2017 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.